WASHINGTON, Aug 25: The US Food and Drug Administration has extended its review of an experimental cell therapy being developed by Capricor Therapeutics for Duchenne muscular dystrophy, the company announced Monday.
The FDA has added three months to its review period after receiving additional information from the biotechnology company. The extension gives regulators more time to assess the newly submitted data before reaching a decision.
The therapy is being developed for Duchenne muscular dystrophy, a serious genetic condition that primarily affects children and leads to progressive muscle weakness.
Duchenne is caused by mutations affecting dystrophin, a protein essential for maintaining muscle structure. Patients typically experience worsening muscle function over time, making the development of new treatment options an important area of medical research.
Capricor’s candidate is an experimental cell based treatment intended to address the underlying progression of the disease. The FDA’s extended review does not represent an approval or rejection of the therapy.
Instead, the additional period allows regulators to examine the new information submitted by the company as part of the ongoing evaluation.
The development is being closely watched by patients, families and the broader rare disease community because treatment choices for Duchenne remain limited despite advances in supportive care and disease management.
Regulatory reviews of experimental therapies can involve extensive assessments of clinical evidence, manufacturing processes and potential safety considerations before a final decision is made.
Capricor said the additional review period will allow the FDA to consider the newly submitted material. The company continues to pursue regulatory approval for the therapy.
The case highlights the lengthy and detailed process involved in bringing treatments for rare genetic disorders from clinical development to patients.
